Entering text into the input field will update the search result below

FDA clears Bio-Path's IND for BP1002

  • The FDA has reviewed and cleared Bio-Path Holdings' (NASDAQ:BPTH) IND application for BP1002 (liposomal Bcl-2), the Company’s second drug candidate.
  • An initial Phase 1 clinical trial will evaluate the ability of BP1002 to treat refractory/relapsed lymphoma and chronic lymphocytic leukemia patients.
  • Shares are up 15% premarket.

Recommended For You

More Trending News

About BPTH Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
BPTH--
Bio-Path Holdings, Inc.